Total Payments
$13,534
2024 Payments
$3,171
Companies
57
Transactions
891
Medicare Patients
24,163
Medicare Billing
$1.8M
Payment Breakdown by Category
Food & Beverage$13,486 (99.6%)
Education$48.61 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,486 | 885 | 99.6% |
| Education | $48.61 | 6 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,609 | 113 | $0 (2024) |
| Novo Nordisk Inc | $1,601 | 118 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,252 | 85 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,200 | 72 | $0 (2024) |
| Lilly USA, LLC | $700.90 | 43 | $0 (2024) |
| PFIZER INC. | $697.12 | 50 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $696.58 | 59 | $0 (2024) |
| Amgen Inc. | $522.91 | 34 | $0 (2024) |
| Corium, LLC | $412.87 | 22 | $0 (2024) |
| Merck Sharp & Dohme LLC | $403.26 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,171 | 194 | ABBVIE INC. ($443.54) |
| 2023 | $2,194 | 134 | AbbVie Inc. ($384.07) |
| 2022 | $1,842 | 118 | GlaxoSmithKline, LLC. ($278.33) |
| 2021 | $1,879 | 119 | AbbVie Inc. ($452.62) |
| 2020 | $1,475 | 105 | Novo Nordisk Inc ($253.81) |
| 2019 | $1,003 | 70 | AstraZeneca Pharmaceuticals LP ($187.24) |
| 2018 | $1,105 | 85 | Novo Nordisk Inc ($199.12) |
| 2017 | $865.31 | 66 | Horizon Pharma plc ($179.98) |
All Payment Transactions
891 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Orchard Therapeutics North America | LENMELDY (Biological) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: METACHROMATIC LEUKODYSTROPHY | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Gastroenterology | ||||||
| 12/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $24.19 | General |
| 12/04/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: Gastroenterology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $15.86 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 11/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Cardio-renal | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $4.62 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: PAIN | ||||||
| 11/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $1.07 | General |
| Category: PAIN | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $10.27 | General |
| Category: Gastroenterology | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $0.32 | General |
| Category: Gastroenterology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Respiratory | ||||||
| 11/09/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: VACCINES | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $10.98 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 60 | 5,031 | 10,404 | $631,326 | $357,683 |
| 2022 | 66 | 7,577 | 18,870 | $1.1M | $665,626 |
| 2021 | 64 | 6,038 | 31,904 | $721,904 | $416,187 |
| 2020 | 52 | 5,517 | 33,337 | $720,568 | $345,284 |
Total Patients
24,163
Total Services
94,515
Medicare Billing
$1.8M
Procedure Codes
242
All Medicare Procedures & Services
242 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 696 | 1,631 | $228,340 | $129,011 | 56.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 409 | 698 | $62,820 | $38,042 | 60.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 266 | 266 | $37,240 | $31,278 | 84.0% |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2023 | 124 | 134 | $20,465 | $18,311 | 89.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 105 | 400 | $24,000 | $11,478 | 47.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 41 | 41 | $14,555 | $11,306 | 77.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 101 | 101 | $19,695 | $10,559 | 53.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 140 | 140 | $12,040 | $10,538 | 87.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 418 | 1,129 | $33,870 | $10,319 | 30.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 78 | 294 | $18,228 | $8,615 | 47.3% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 141 | 158 | $12,640 | $7,960 | 63.0% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2023 | 83 | 89 | $11,570 | $6,174 | 53.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 83 | 258 | $12,900 | $6,137 | 47.6% |
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | Office | 2023 | 44 | 44 | $6,160 | $6,037 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 148 | 150 | $4,500 | $4,247 | 94.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 27 | 31 | $10,044 | $4,074 | 40.6% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 19 | 19 | $5,885 | $3,821 | 64.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 33 | 39 | $9,750 | $3,757 | 38.5% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 50 | 88 | $6,072 | $2,543 | 41.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 34 | 34 | $4,420 | $2,362 | 53.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 97 | 111 | $7,104 | $2,273 | 32.0% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2023 | 56 | 59 | $2,950 | $1,965 | 66.6% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 15 | 15 | $2,100 | $1,962 | 93.4% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 17 | 20 | $4,120 | $1,956 | 47.5% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 38 | 38 | $4,864 | $1,911 | 39.3% |
About Dr. David Campbell, M.D
Dr. David Campbell, M.D is a Family Medicine healthcare provider based in Guntersville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1811100985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Campbell, M.D has received a total of $13,534 in payments from pharmaceutical and medical device companies, with $3,171 received in 2024. These payments were reported across 891 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($13,486).
As a Medicare-enrolled provider, Campbell has provided services to 24,163 Medicare beneficiaries, totaling 94,515 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 242 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Guntersville, AL
- Active Since 05/07/2007
- Last Updated 02/24/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1811100985
Products in Payments
- VRAYLAR (Drug) $1,045
- TRELEGY ELLIPTA (Drug) $954.11
- FARXIGA (Drug) $708.96
- UBRELVY (Drug) $571.57
- XIFAXAN (Drug) $570.22
- Ozempic (Drug) $507.96
- MOUNJARO (Drug) $388.01
- Saxenda (Drug) $384.07
- Azstarys (Drug) $328.02
- Kerendia (Drug) $308.28
- TRINTELLIX (Drug) $257.84
- JARDIANCE (Drug) $247.23
- Rybelsus (Drug) $234.48
- AIRSUPRA (Drug) $232.31
- NURTEC ODT (Drug) $231.47
- JANUVIA (Drug) $199.81
- Wegovy (Drug) $189.61
- Vascepa (Drug) $188.40
- Livalo (Drug) $182.20
- XYOSTED (Drug) $179.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Guntersville
Mr. William Nixon, Md, MD
Family Medicine — Payments: $31,964
Family Medicine $31,964
Dr. Joel Milligan, Md, MD
Family Medicine — Payments: $10,418
Family Medicine $10,418
Mr. Jeffrey Saylor, Md, MD
Family Medicine — Payments: $10,380
Family Medicine $10,380
John Boggess, Md, MD
Family Medicine — Payments: $9,633
Family Medicine $9,633
Allison Brewster, Crnp, CRNP
Family Medicine — Payments: $8,867
Family Medicine $8,867
Joshua Bell, M.d, M.D
Family Medicine — Payments: $8,529
Family Medicine $8,529